Concord Biotech Limited Just Beat Revenue Estimates By 5.0%
It's been a pretty great week for Concord Biotech Limited (NSE:CONCORDBIO) shareholders, with its shares surging 13% to ₹1,420 in the week since its latest first-quarter results. Concord Biotech beat revenue expectations by 5.0%, at ₹2.6b. Statutory earnings per share (EPS) came in at ₹5.52, some 4.8% short of analyst estimates. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
Taking into account the latest results, the current consensus from Concord Biotech's five analysts is for revenues of ₹12.8b in 2027. This would reflect a solid 16% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to bounce 23% to ₹32.39. Before this earnings report, the analysts had been forecasting revenues of ₹12.6b and earnings per share (EPS) of ₹33.48 in 2027. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analysts did make a minor downgrade to their earnings per share forecasts.
See our latest analysis for Concord Biotech
Althoughthe analysts have revised their earnings forecasts for next year, they've also lifted the consensus price target 20% to ₹1,455, suggesting the revised estimates are not indicative of a weaker long-term future for the business. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values Concord Biotech at ₹1,645 per share, while the most bearish prices it at ₹1,220. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth.
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. The analysts are definitely expecting Concord Biotech's growth to accelerate, with the forecast 22% annualised growth to the end of 2027 ranking favourably alongside historical growth of 6.9% per annum over the past three years. Compare this with other companies in the same industry, which are forecast to grow their revenue 12% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Concord Biotech is expected to grow much faster than its industry.
The Bottom Line
The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.
With that in mind, we wouldn't be too quick to come to a conclusion on Concord Biotech. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Concord Biotech analysts - going out to 2029, and you can see them free on our platform here.
Before you take the next step you should know about the 1 warning sign for Concord Biotech that we have uncovered.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.